文献速递其他结缔组织病

生物制剂治疗儿童局限性硬皮病与系统性硬化症的应用:范围综述

Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review.
PubMed 文献 · Semin Arthritis Rheum · 2025-01-29

本范围综述检索MEDLINE与Scopus,纳入17篇文献描述58例接受生物制剂的儿童局限性硬皮病患者、12篇文献描述29例接受生物制剂的儿童系统性硬化症患者。局限性硬皮病最常用阿巴西普(55.2%)与托珠单抗(48.3%),改善率分别为92.9%与77.4%;系统性硬化症最常用利妥昔单抗(51.7%)与托珠单抗(44.8%),改善率分别为72.7%与94.1%。

要点

  • 儿童局限性硬皮病中阿巴西普使用率55.2%、改善率92.9%,托珠单抗使用率48.3%、改善率77.4%。
  • 儿童系统性硬化症中利妥昔单抗使用率51.7%、改善率72.7%,托珠单抗使用率44.8%、改善率94.1%。
  • 局限性硬皮病不良事件发生率23.5%,系统性硬化症不良事件发生率40%。

核心结论

  • 儿童局限性硬皮病中阿巴西普与托珠单抗使用较多,儿童系统性硬化症中利妥昔单抗与托珠单抗使用较多。
  • 这些生物制剂的改善率较高,安全性可接受。

研究设计与样本

  • 范围综述,检索MEDLINE与Scopus中涉及接受生物制剂治疗的儿童局限性硬皮病与系统性硬化症患者的文献。
  • 纳入17篇文献描述58例儿童局限性硬皮病患者,12篇文献描述29例儿童系统性硬化症患者。

主要发现

  • 儿童局限性硬皮病最常用生物制剂为阿巴西普(55.2%),其次为托珠单抗(48.3%);主要用于治疗难治性/进展性皮肤病变(分别为58.5%与68.8%)。
  • 阿巴西普与托珠单抗相关改善率分别为92.9%与77.4%;全部局限性硬皮病患者中不良事件发生率为23.5%。
  • 儿童系统性硬化症最常用生物制剂为利妥昔单抗(51.7%),其次为托珠单抗(44.8%);利妥昔单抗主要用于心脏受累(45.5%),托珠单抗主要用于肺部受累(50%)。
  • 利妥昔单抗与托珠单抗相关改善率分别为72.7%与94.1%;全部系统性硬化症患者中不良事件报告率为40%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Biologic drugs are a potential treatment option in resistant cases of juvenile scleroderma. In this review, we aimed to examine previous studies regarding biologic drug use in pediatric patients with localized scleroderma and systemic sclerosis. METHODS: We performed a search on MEDLINE and Scopus for articles involving pediatric localized scleroderma and systemic sclerosis patients treated with biologic drugs. RESULTS: We identified 17 articles describing 58 pediatric patients with localized scleroderma treated with biologic drugs and 12 articles describing 29 pediatric patients with systemic sclerosis treated with biologic drugs during our literature search. The most frequently used biologic drug in localized scleroderma treatment was abatacept (55.2 %), followed by tocilizumab (48.3 %). These biologic drugs were mainly preferred for treating resistant/progressive skin disease in pediatric patients with localized scleroderma (58.5 % and 68.8 %, respectively). The improvement rates associated with abatacept and tocilizumab were 92.9 % and 77.4 %, respectively. Adverse events were observed in 23.5 % of all localized scleroderma patients. The most frequently used biologic drug in systemic sclerosis treatment was rituximab (51.7 %), followed by tocilizumab (44.8 %). Rituximab was predominantly favored for managing cardiac involvement (45.5 %), whereas tocilizumab was preferred for pulmonary involvement (50 %) in pediatric patients with systemic sclerosis. The improvement rates associated with rituximab and tocilizumab were 72.7 % and 94.1 %, respectively. Adverse events were reported in 40 % of all systemic sclerosis patients. CONCLUSION: Our results showed that abatacept and tocilizumab were more frequently used in patients with localized scleroderma, while rituximab and tocilizumab were the predominantly used biologics in patients with systemic sclerosis. The improvement rate with these biologics were quite high with acceptable safety profile.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Sener S, Batu ED. Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review. Semin Arthritis Rheum. 2025. PMID: 39938346. doi:10.1016/j.semarthrit.2025.152634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。